Unveiling 7 Analyst Insights On EyePoint Pharmaceuticals
Portfolio Pulse from Benzinga Insights
EyePoint Pharmaceuticals (NASDAQ:EYPT) has been evaluated by 7 analysts over the last three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $31.71, up 18.54% from the previous $26.75, with a high estimate of $44.00 and a low of $20.00. Recent analyst actions include ratings and price target adjustments by JP Morgan, HC Wainwright & Co., Capital One, and Mizuho. EyePoint Pharmaceuticals focuses on ophthalmic products and has shown a revenue growth of 51.84% as of September 30, 2023. However, it has a net margin of -82.96% and an ROE of -21.77%, indicating profitability challenges.
January 22, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EyePoint Pharmaceuticals has received mixed ratings from analysts, with an upward trend in the average price target to $31.71. The company has shown significant revenue growth but struggles with profitability.
The increase in the average price target and the recent bullish ratings from analysts suggest a positive short-term impact on EYPT's stock price. However, the concerns about profitability and below-average net margin and ROE may temper the stock's upward momentum.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100